CY1116762T1 - Πολυπεπτιδια, μεταβλητες περιοχες αντισωματος και ανταγωνιστες - Google Patents
Πολυπεπτιδια, μεταβλητες περιοχες αντισωματος και ανταγωνιστεςInfo
- Publication number
- CY1116762T1 CY1116762T1 CY20151100886T CY151100886T CY1116762T1 CY 1116762 T1 CY1116762 T1 CY 1116762T1 CY 20151100886 T CY20151100886 T CY 20151100886T CY 151100886 T CY151100886 T CY 151100886T CY 1116762 T1 CY1116762 T1 CY 1116762T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptides
- antagonists
- variable antibody
- dab
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
Abstract
Η εφεύρεση αφορά τα αντι-THFR1 πολυπεπτίδια και τις μονές μεταβλητές περιοχές αντισώματος (dAb) που είναι ανθεκτικές στην αποικοδόμηση από μια πρωτεάση, καθώς και ανταγωνιστές που τα περιέχουν. Τα πολυπεπτίδια, dAb και ανταγωνιστές είναι χρήσιμα ως θεραπευτικά και/ή προφυλακτικά μέσα που είναι πιθανό να αντιμετωπίσουν τις πρωτεάσες όταν χορηγούνται σε έναν ασθενή, για παράδειγμα για πνευμονική χορήγηση, στοματική χορήγηση, διανομή στον πνεύμονα και διανομή στη γαστρεντερική οδό ενός ασθενούς, καθώς και για την αντιμετώπιση μιας φλεγμονώδους νόσου, όπως η αρθρίτιδα ή η COPD.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93363207P | 2007-06-06 | 2007-06-06 | |
GBGB0724331.4A GB0724331D0 (en) | 2007-12-13 | 2007-12-13 | Compositions for pulmonary delivery |
EP08750800.8A EP2162467B1 (en) | 2007-06-06 | 2008-06-04 | Polypeptides, antibody variable domains & antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116762T1 true CY1116762T1 (el) | 2017-03-15 |
Family
ID=39791116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100886T CY1116762T1 (el) | 2007-06-06 | 2015-10-06 | Πολυπεπτιδια, μεταβλητες περιοχες αντισωματος και ανταγωνιστες |
Country Status (32)
Country | Link |
---|---|
US (5) | US8398979B2 (el) |
EP (5) | EP2746290B1 (el) |
JP (3) | JP5444215B2 (el) |
KR (4) | KR20100018040A (el) |
CN (4) | CN101778865B (el) |
AR (3) | AR066847A1 (el) |
AU (4) | AU2008259590A1 (el) |
BR (3) | BRPI0812268A2 (el) |
CA (6) | CA2688433A1 (el) |
CL (3) | CL2008001673A1 (el) |
CO (2) | CO6251322A2 (el) |
CR (2) | CR11194A (el) |
CY (1) | CY1116762T1 (el) |
DK (1) | DK2162467T3 (el) |
DO (1) | DOP2009000268A (el) |
EA (5) | EA200901494A1 (el) |
ES (1) | ES2546943T3 (el) |
HK (1) | HK1138022A1 (el) |
HR (1) | HRP20151024T1 (el) |
HU (1) | HUE025899T2 (el) |
IL (2) | IL201398A0 (el) |
MA (2) | MA31403B1 (el) |
MX (4) | MX2009013137A (el) |
NZ (1) | NZ581372A (el) |
PE (3) | PE20090322A1 (el) |
PL (1) | PL2162467T3 (el) |
PT (1) | PT2162467E (el) |
SG (2) | SG182151A1 (el) |
SI (1) | SI2162467T1 (el) |
TW (6) | TW200911832A (el) |
WO (3) | WO2008149148A2 (el) |
ZA (1) | ZA200908470B (el) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
WO2006122787A1 (en) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
CA2683801A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
AU2008334605B2 (en) * | 2007-12-13 | 2013-07-18 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
CA3020290A1 (en) | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
MX2011005540A (es) * | 2008-11-26 | 2011-06-21 | Glaxo Group Ltd | Polipeptidos dominios variables de anticuerpos, y antagonistas. |
WO2010081787A1 (en) | 2009-01-14 | 2010-07-22 | Domantis Limited | IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS |
CN102405232B (zh) * | 2009-02-19 | 2015-08-19 | 葛兰素集团有限公司 | 改良的抗血清清蛋白结合变体 |
SG173489A1 (en) | 2009-02-19 | 2011-09-29 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
EA022925B1 (ru) * | 2009-02-19 | 2016-03-31 | Глаксо Груп Лимитед | Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1 |
EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
EP2453920A2 (en) * | 2009-07-16 | 2012-05-23 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
CA2768462A1 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Ltd. | Improved anti-serum albumin binding single variable domains |
CA2777700A1 (en) * | 2009-10-14 | 2011-04-21 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
UA107200C2 (uk) | 2009-10-27 | 2014-12-10 | Ґлаксо Ґруп Лімітед | ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα |
EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
US9040668B2 (en) | 2010-05-20 | 2015-05-26 | Glaxo Group Limited | Anti-serum albumin binding variants |
JP2013538566A (ja) * | 2010-08-13 | 2013-10-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 改良された抗血清アルブミン結合変異体 |
KR20130055663A (ko) * | 2010-08-20 | 2013-05-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 개선된 항-혈청 알부민 결합 변이체 |
CA2810465C (en) * | 2010-09-16 | 2018-10-02 | Baliopharm Ag | Anti-hutnfr1 antibody |
EP2646467A2 (en) | 2010-12-01 | 2013-10-09 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
JP2014505698A (ja) * | 2011-02-02 | 2014-03-06 | グラクソ グループ リミテッド | 新規抗原結合タンパク質 |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
PL2726092T3 (pl) | 2011-06-28 | 2019-11-29 | Inhibrx Lp | Polipeptydy fuzyjne serpiny i sposoby ich stosowania |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
US9499612B2 (en) * | 2011-07-27 | 2016-11-22 | Glaxo Group Limited | Antigen binding constructs |
CN108178800B (zh) | 2011-08-17 | 2022-06-17 | 葛兰素集团有限公司 | 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体 |
GB2497138A (en) * | 2011-12-02 | 2013-06-05 | Randox Lab Ltd | Biomarkers for stroke and stroke subtype diagnosis. |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
SG11201505388QA (en) * | 2013-01-31 | 2015-08-28 | Glaxo Group Ltd | Method of producing a protein |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
GB201617622D0 (en) * | 2016-10-18 | 2016-11-30 | VIB VZW and Universiteit Gent | Means and methods to treat inflammation |
RU2625010C1 (ru) * | 2016-11-10 | 2017-07-11 | Илья Петрович Приколаб | Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка |
CA3041279A1 (en) | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding domain, and polypeptide including conveying section |
UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
CN111295189B (zh) * | 2017-11-01 | 2023-09-15 | 艾洛基治疗公司 | 修饰的胱天蛋白酶-9多肽及其使用方法 |
WO2019230866A1 (en) * | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising il-1r1 binding domain and carrying moiety |
PL3623798T3 (pl) * | 2018-09-13 | 2022-03-28 | Euroimmun Medizinische Labordiagnostika Ag | Sposób i urządzenie do wykrywania i przedstawiania obrazu immunofluorescencyjnego próbki biologicznej |
WO2020084032A1 (en) * | 2018-10-25 | 2020-04-30 | F. Hoffmann-La Roche Ag | Modification of antibody fcrn binding |
CN111454366B (zh) * | 2019-01-21 | 2023-06-16 | 中国科学院深圳先进技术研究院 | 一种融合蛋白及其应用 |
EP3919903A4 (en) * | 2019-01-31 | 2022-11-02 | Sekisui Medical Co., Ltd. | METHOD FOR IMMUNOLOGICAL ANALYSIS OF FREE AIM IN A BIOLOGICAL SAMPLE AND MEASUREMENT KIT |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
KR20230078657A (ko) | 2020-08-27 | 2023-06-02 | 에노시 테라퓨틱스 코퍼레이션 | 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물 |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
CN115181751A (zh) * | 2021-04-02 | 2022-10-14 | 苏州博腾生物制药有限公司 | 靶向白蛋白的嵌合抗原受体及其使用方法 |
CN114657162B (zh) * | 2022-03-04 | 2023-06-16 | 华南理工大学 | 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
EP0562025B1 (en) | 1990-12-06 | 2001-02-07 | Affymetrix, Inc. (a Delaware Corporation) | Compounds and their use in a binary synthesis strategy |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
BRPI9715219B8 (pt) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
EP1801214B1 (en) | 1997-07-07 | 2010-11-10 | Medical Research Council | In vitro sorting method |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
CA2328422A1 (en) | 1998-05-13 | 1999-11-18 | Diversys Limited | Selection system |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
JP2003523742A (ja) | 2000-02-03 | 2003-08-12 | ドマンティス リミテッド | コンビナトリアルタンパク質ドメイン |
WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
US7265210B2 (en) * | 2000-09-15 | 2007-09-04 | Genentech, Inc. | Anti-PRO9821 antibodies |
JP4434580B2 (ja) | 2000-11-28 | 2010-03-17 | メディミューン,エルエルシー | 予防及び治療のために抗rsv抗体を投与/処方する方法 |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
GB0118689D0 (en) * | 2001-08-01 | 2001-09-19 | Psimedica Ltd | Pharmaceutical formulation |
EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
EP1517921B1 (en) * | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
ATE549033T1 (de) | 2002-09-06 | 2012-03-15 | Amgen Inc | Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper |
WO2004022096A1 (en) | 2002-09-06 | 2004-03-18 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
ES2315664T3 (es) * | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
NZ548612A (en) | 2004-02-09 | 2009-11-27 | Human Genome Sciences Inc | Albumin fusion proteins comprising tandem GLP-1 |
PT1737962E (pt) | 2004-03-24 | 2010-12-03 | Domantis Ltd | Sequência líder universal gas1 |
EP2319492A3 (en) * | 2004-10-21 | 2011-08-10 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
CN101133084A (zh) | 2004-12-02 | 2008-02-27 | 多曼蒂斯有限公司 | 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法 |
JP2009519011A (ja) | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン1受容体1型に結合する非競合ドメイン抗体フォーマット |
CN101466734A (zh) | 2005-12-01 | 2009-06-24 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的竞争性域抗体形式 |
CA2660519A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
EP2081960B1 (en) * | 2006-10-27 | 2018-06-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
CA2683801A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
-
2008
- 2008-06-03 CA CA002688433A patent/CA2688433A1/en not_active Abandoned
- 2008-06-03 CA CA002683791A patent/CA2683791A1/en not_active Abandoned
- 2008-06-03 CA CA002688434A patent/CA2688434A1/en not_active Abandoned
- 2008-06-03 KR KR1020107000188A patent/KR20100018040A/ko not_active Application Discontinuation
- 2008-06-03 EA EA200901494A patent/EA200901494A1/ru unknown
- 2008-06-03 MX MX2009013137A patent/MX2009013137A/es not_active Application Discontinuation
- 2008-06-03 AU AU2008259590A patent/AU2008259590A1/en not_active Abandoned
- 2008-06-04 KR KR1020107000212A patent/KR101604274B1/ko active IP Right Grant
- 2008-06-04 MX MX2009013211A patent/MX2009013211A/es active IP Right Grant
- 2008-06-04 CA CA2688447A patent/CA2688447C/en active Active
- 2008-06-04 EP EP13184209.8A patent/EP2746290B1/en active Active
- 2008-06-04 JP JP2010510887A patent/JP5444215B2/ja active Active
- 2008-06-04 AR ARP080102362A patent/AR066847A1/es unknown
- 2008-06-04 CN CN200880102207.2A patent/CN101778865B/zh active Active
- 2008-06-04 JP JP2010510888A patent/JP2010530364A/ja active Pending
- 2008-06-04 EA EA200901495A patent/EA018723B1/ru not_active IP Right Cessation
- 2008-06-04 AR ARP080102365A patent/AR066850A1/es not_active Application Discontinuation
- 2008-06-04 AU AU2008259514A patent/AU2008259514B2/en not_active Ceased
- 2008-06-04 AR ARP080102363A patent/AR066848A1/es not_active Application Discontinuation
- 2008-06-04 WO PCT/GB2008/050405 patent/WO2008149148A2/en active Application Filing
- 2008-06-04 CA CA002683823A patent/CA2683823A1/en not_active Abandoned
- 2008-06-04 PE PE2008000940A patent/PE20090322A1/es not_active Application Discontinuation
- 2008-06-04 HU HUE08750800A patent/HUE025899T2/en unknown
- 2008-06-04 EA EA200901300A patent/EA200901300A1/ru unknown
- 2008-06-04 MX MX2009012967A patent/MX2009012967A/es not_active Application Discontinuation
- 2008-06-04 BR BRPI0812268A patent/BRPI0812268A2/pt not_active IP Right Cessation
- 2008-06-04 WO PCT/GB2008/050406 patent/WO2008149149A2/en active Application Filing
- 2008-06-04 EP EP08750802A patent/EP2162468A2/en not_active Withdrawn
- 2008-06-04 CN CN2008801020043A patent/CN101883788A/zh active Pending
- 2008-06-04 WO PCT/GB2008/050407 patent/WO2008149150A2/en active Application Filing
- 2008-06-04 US US12/663,502 patent/US8398979B2/en active Active
- 2008-06-04 CN CN201410440384.9A patent/CN104311663B/zh active Active
- 2008-06-04 BR BRPI0813899A patent/BRPI0813899A2/pt not_active IP Right Cessation
- 2008-06-04 ES ES08750800.8T patent/ES2546943T3/es active Active
- 2008-06-04 PE PE2008000943A patent/PE20090763A1/es not_active Application Discontinuation
- 2008-06-04 PT PT87508008T patent/PT2162467E/pt unknown
- 2008-06-04 NZ NZ581372A patent/NZ581372A/en not_active IP Right Cessation
- 2008-06-04 JP JP2010510886A patent/JP5325211B2/ja not_active Expired - Fee Related
- 2008-06-04 SG SG2012040275A patent/SG182151A1/en unknown
- 2008-06-04 CN CN200880019060A patent/CN101802004A/zh active Pending
- 2008-06-04 EP EP08750801A patent/EP2164867A2/en not_active Withdrawn
- 2008-06-04 EP EP13184211.4A patent/EP2746291B1/en active Active
- 2008-06-04 MX MX2009013138A patent/MX2009013138A/es active IP Right Grant
- 2008-06-04 KR KR1020107000213A patent/KR20100041746A/ko not_active Application Discontinuation
- 2008-06-04 CA CA002688456A patent/CA2688456A1/en not_active Abandoned
- 2008-06-04 DK DK08750800.8T patent/DK2162467T3/en active
- 2008-06-04 KR KR1020107000223A patent/KR20100040841A/ko not_active Application Discontinuation
- 2008-06-04 EA EA200901491A patent/EA018129B1/ru not_active IP Right Cessation
- 2008-06-04 US US12/663,506 patent/US20100247515A1/en not_active Abandoned
- 2008-06-04 PL PL08750800T patent/PL2162467T3/pl unknown
- 2008-06-04 BR BRPI0812795A patent/BRPI0812795C1/pt not_active IP Right Cessation
- 2008-06-04 SG SG2012039541A patent/SG182141A1/en unknown
- 2008-06-04 PE PE2008000944A patent/PE20090323A1/es not_active Application Discontinuation
- 2008-06-04 EP EP08750800.8A patent/EP2162467B1/en active Active
- 2008-06-04 SI SI200831508T patent/SI2162467T1/sl unknown
- 2008-06-04 AU AU2008259516A patent/AU2008259516A1/en not_active Abandoned
- 2008-06-04 AU AU2008259515A patent/AU2008259515A1/en not_active Abandoned
- 2008-06-06 CL CL2008001673A patent/CL2008001673A1/es unknown
- 2008-06-06 TW TW097121295A patent/TW200911832A/zh unknown
- 2008-06-06 TW TW097121280A patent/TW200907128A/zh unknown
- 2008-06-06 CL CL2008001676A patent/CL2008001676A1/es unknown
- 2008-06-06 CL CL2008001674A patent/CL2008001674A1/es unknown
- 2008-06-06 TW TW097121268A patent/TW200911831A/zh unknown
- 2008-06-06 TW TW097121301A patent/TW200918088A/zh unknown
- 2008-06-06 TW TW097121296A patent/TW200902551A/zh unknown
- 2008-06-06 TW TW097121265A patent/TW200911834A/zh unknown
- 2008-11-26 US US12/323,632 patent/US20090148437A1/en not_active Abandoned
-
2009
- 2009-10-11 IL IL201398A patent/IL201398A0/en unknown
- 2009-11-04 EA EA201100546A patent/EA201100546A1/ru unknown
- 2009-11-04 US US13/130,656 patent/US20110256122A1/en not_active Abandoned
- 2009-11-18 IL IL202204A patent/IL202204A0/en unknown
- 2009-11-27 DO DO2009000268A patent/DOP2009000268A/es unknown
- 2009-11-30 ZA ZA2009/08470A patent/ZA200908470B/en unknown
- 2009-11-30 MA MA32388A patent/MA31403B1/fr unknown
- 2009-12-14 CO CO09142782A patent/CO6251322A2/es not_active Application Discontinuation
- 2009-12-14 CO CO09142781A patent/CO6251321A2/es not_active Application Discontinuation
-
2010
- 2010-01-04 MA MA32475A patent/MA31668B1/fr unknown
- 2010-01-06 CR CR11194A patent/CR11194A/es not_active Application Discontinuation
- 2010-01-06 CR CR11195A patent/CR11195A/es unknown
- 2010-05-24 HK HK10105002.3A patent/HK1138022A1/xx not_active IP Right Cessation
-
2011
- 2011-11-17 US US13/299,030 patent/US20120134982A1/en not_active Abandoned
-
2015
- 2015-09-28 HR HRP20151024TT patent/HRP20151024T1/hr unknown
- 2015-10-06 CY CY20151100886T patent/CY1116762T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116762T1 (el) | Πολυπεπτιδια, μεταβλητες περιοχες αντισωματος και ανταγωνιστες | |
EA200901301A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
CY1113299T1 (el) | Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο | |
WO2008149144A3 (en) | Polypeptides, antibody variable domains and antagonists | |
NL301089I2 (nl) | imlifidase | |
CY1120048T1 (el) | Συνθεσεις για την αγωγη γαστρεντερικης φλεγμονης | |
CY1108843T1 (el) | 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων | |
CY1110500T1 (el) | Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας | |
CY1115871T1 (el) | Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας | |
CY1106774T1 (el) | Συνθεσεις φαρμακευτικων μεσων με βαση αλατα του τιοτροπιου και αλατα της σαλμετερολης | |
CY1113630T1 (el) | Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn | |
CY1107426T1 (el) | Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων | |
UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
CY1113267T1 (el) | Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1 | |
CY1111065T1 (el) | Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
EA201000785A1 (ru) | Композиции для доставки в легкие | |
MX2011008799A (es) | Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados. | |
CY1112682T1 (el) | Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων | |
CY1115937T1 (el) | Εισπνεομενο φαρμακο που περιεχει αμορφο βρωμιουχο τιοτροπιο | |
CY1112591T1 (el) | Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης | |
ATE497392T1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
CY1114933T1 (el) | Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους | |
CY1115384T1 (el) | Αντι-φλεγμονωδης συνθεση | |
LU92202I2 (fr) | Aflibercept | |
CY1119819T1 (el) | Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας |